Core Viewpoint - The company, Guangdong Guokang Biochemical Technology Co., Ltd., aims to continue its foreign exchange derivatives trading to mitigate risks associated with currency fluctuations and enhance financial stability [1][10]. Group 1: Purpose of Foreign Exchange Derivatives Trading - The primary objective of engaging in foreign exchange derivatives trading is to effectively hedge against foreign exchange market risks and prevent adverse impacts from significant currency fluctuations [1]. - The company plans to engage with qualified banks and financial institutions to conduct these transactions [1]. Group 2: Basic Details of the Trading Business - The company intends to utilize its own funds for foreign exchange derivatives trading, with a total limit not exceeding $50 million [2]. - The expected maximum margin and premium for these transactions will not exceed $4 million [2]. - The trading will involve currencies used in the company's overseas operations, primarily the US dollar, and will include various products such as forward foreign exchange settlements, foreign exchange swaps, and options [1][2]. Group 3: Risk Management Measures - The company will adhere to principles of legality, prudence, safety, and effectiveness in its trading activities, avoiding speculative transactions [4][8]. - A clear set of operational norms, approval authorities, and risk management procedures will be established to control trading risks [8]. Group 4: Impact on the Company - The foreign exchange derivatives trading is closely related to the company's operational activities, enhancing its ability to manage foreign exchange risks and reducing financial costs [5][10]. - The trading activities are expected to strengthen the company's financial stability without harming the interests of the company or its shareholders [5][10]. Group 5: Accounting Policies and Procedures - The company will follow relevant accounting standards for financial instruments and hedge accounting to reflect the transactions in its financial statements [9]. Group 6: Approval Process - The board of directors approved the continuation of foreign exchange derivatives trading on August 20, 2025, with the authorization effective from September 23, 2025, for a period of 12 months [9][10]. - The audit committee has confirmed the necessity and compliance of the decision-making process regarding the trading activities [10].
广康生化: 华泰联合证券有限责任公司关于广东广康生化科技股份有限公司继续开展外汇衍生品交易业务的核查意见